Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2011

Charles River to Distribute Pfizer Research Models

Charles River to Distribute Pfizer Research Models

The models are in therapeutic areas that include neuroscience, diabetes and cardiovascular disease. [© ktsdesign - Fotolia.com]

  • Charles River Laboratories inked an agreement with Pfizer to market and distribute to researchers worldwide precompetitive, transgenic research models. The Pfizer-developed models are in therapeutic areas that include neuroscience, diabetes, and cardiovascular disease.

    The models will be used in research to target specific disease states and genetic markers, says Dr. Iva Morse, corporate vp, global research model services at Charles River.

    Rick Connell, Pfizer’s vp and worldwide head of external research solutions center of excellence, says the agreement “aligns with Pfizer’s strategy to externalize our precompetitive tools and assets to a broader community of scientists outside of Pfizer’s walls.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »